Publications

Breast cancer research : BCR

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.

25-07-2020

JAMA oncology

De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ.

01-07-2020

Cancer research

Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.

15-05-2020

International journal of radiation oncology, biology, physics

Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial.

01-04-2020

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03).

01-04-2020

Molecular oncology

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.

01-04-2020

Breast (Edinburgh, Scotland)

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review.

01-04-2020

International journal of radiation oncology, biology, physics

Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients.

01-01-2020

European journal of radiology

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

01-12-2019

Breast cancer research and treatment

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study.

01-11-2019

The American journal of surgical pathology

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.

01-11-2019

Key Publication

Communications biology

Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping.

12-09-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.

15-08-2019

Key Publication

British journal of cancer

Ductal carcinoma in situ: to treat or not to treat, that is the question.

01-08-2019

Key Publication

Breast (Edinburgh, Scotland)

Utility of diagnostic breast excision biopsies during two decades of screening mammography.

01-08-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

15-07-2019

Trends in cancer

Avoiding Overtreatment of Ductal Carcinoma in situ.

01-07-2019

Breast cancer research and treatment

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.

01-05-2019

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses.

01-05-2019

The Lancet. Oncology

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

01-12-2018

Molecular oncology

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

01-11-2018

European journal of cancer (Oxford, England : 1990)

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

01-10-2018

European journal of cancer (Oxford, England : 1990)

Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012.

01-09-2018

Clinical cancer research : an official journal of the American Association for Cancer Research

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.

01-08-2018

Key Publication

BMC cancer

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.

24-07-2018

Annals of surgery

Response to: "DCIS and Breast Cancer: Challenging the Paradigm".

01-07-2018

Genes

Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study.

17-05-2018

Annals of surgery

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.

01-05-2018

Breast cancer research and treatment

Enrichment of high-grade tumors in breast cancer gene expression studies.

01-04-2018

BMC cancer

The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.

27-02-2018

PloS one

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.

22-12-2017

Nature genetics

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.

01-12-2017

BMJ open

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.

14-11-2017

Breast cancer research and treatment

The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study.

01-11-2017

Annals of surgical oncology

Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials.

01-11-2017

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.

20-08-2017

Journal of the National Cancer Institute

Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.

01-08-2017

Nature genetics

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

01-08-2017

Breast cancer research and treatment

MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.

01-07-2017

Cancer imaging : the official publication of the International Cancer Imaging Society

Additional value of ¹⁸F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

25-05-2017

PloS one

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.

23-05-2017

Critical reviews in oncology/hematology

Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review.

01-04-2017

Breast cancer research : BCR

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.

09-03-2017

European journal of cancer (Oxford, England : 1990)

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

01-03-2017

Clinical cancer research : an official journal of the American Association for Cancer Research

BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency.

01-03-2017

Breast (Edinburgh, Scotland)

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

01-02-2017

Breast cancer research and treatment

Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

01-01-2017

Journal of the National Cancer Institute

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.

01-11-2016

Breast cancer research : BCR

Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.

18-10-2016

Breast cancer research and treatment

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

01-10-2016

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.

De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ.

Endonuclease FEN1 Coregulates ERα Activity and Provides a Novel Drug Interface in Tamoxifen-Resistant Breast Cancer.

Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial.

Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03).

Somatic mutations and copy number variations in breast cancers with heterogeneous HER2 amplification.

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review.

Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients.

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study.

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.

Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping.

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.

Ductal carcinoma in situ: to treat or not to treat, that is the question.

Utility of diagnostic breast excision biopsies during two decades of screening mammography.

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

Avoiding Overtreatment of Ductal Carcinoma in situ.

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.

Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses.

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012.

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.

Response to: "DCIS and Breast Cancer: Challenging the Paradigm".

Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study.

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.

Enrichment of high-grade tumors in breast cancer gene expression studies.

The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.

The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study.

Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials.

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.

Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.

Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review.

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency.

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.

Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

This site uses cookies

Additional value of ¹⁸F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.